Designed and engineered as a complete solution, the XCell™ Lab System integrates a modern controller, XCell ATF® Devices, software and flow sensors into a complete solution.
XCell ATF® technology helps simplify and intensify upstream processes to deliver more product, faster. Intensified processes achieve higher cell densities, require smaller bioreactors and consume less suite time. Increase throughput, productivity, and capacity in both clinical and commercial manufacturing.
More programs, more molecules
More product per batch
More batches per facility
Reduce bioreactor size up to 10 fold
For example from 10,000 L to 1,000 L
Advance your program
Smaller, flexible intensified processes
Re-think your facility
Lower cost, lower risk, faster results
Sodtware, hardware, device
enables robust development
More process data
for improved characterization
Reduced media cost
XCell ATF®, a leading cell retention technology, simplifies and fast-tracks upstream intensification development for gene therapy, fed-batch intensification, seed train intensification, perfusion, and media exchange applications.
The XCell ATF® intensification simplifies and fast-tracks upstream intensification development from PD to commercial scale. Intensification increases throughput, accelerates tech transfer and optimizes your process in clinical manufacturing and MSAT while increasing bioreactor productivity and reducing costs in commercial manufacturing. Higher productivity, smaller bioreactors and higher throughput with shorter times to harvest, combine to mitigate facility expansion risks and capital costs.
The XCell ATF® solution delivers an efficiency boost both pre- and post-transfection in the gene therapy workflow. Increase yield and save time during host cell expansion and pre-transfection preparation. Post-transfection options exist for multiple host types.
Source: ExpreS2ion Technologies
Higher productivity and lower COGs for malaria therapeutic candidate.
The XCell ATF® System is based on award-winning alternating tangential flow (ATF) technology, created by the action of a diaphragm moving upward and downward within a pump head, connected to a filter housing and attached to a bioreactor. Alternating tangential flow is attained by the action of a diaphragm pump.
The XCell ATF® System delivers a complete solution for upstream intensification with robust hardware software integration. Available in single-use and stainless steel formats with sizes from lab-scale (2 L) to process scale (5000 L). Each system consists of an XCell ATF® Device, XCell™ controller, software, tubing and sensors.
Repligen develops and manufactures products for the biopharmaceutical industry under an ISO 9001 quality management system. We focus on the timely delivery of high quality, consistent and robust products, to ensure business continuity for our customers.
The Repligen Field Application team with expertise in XCell ATF® technology will provide support from consultation to implementation globally.
Frequently asked questions | perfusion